A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Incidence of Adverse Events (AEs)

  Measured over: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

• Number of participants with laboratory abnormalities

  Measured over: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

• Number of participants with vital sign abnormalities

  Measured over: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

• Number of participants with electrocardiogram (ECG) abnormalities

  Measured over: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

• Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities

  Measured over: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

• Number of participants with left ventricular ejection fraction (LVEF) assessment abnormalities

  Measured over: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

• Number of participants with physical examination abnormalities

  Measured over: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

• Dose Limiting Toxicity (DLT)

  Measured over: Up to 28 days in Cycle 1

• Maximum tolerated dose (MTD)

  Measured over: Up to 28 days in cycle 1

Changes Tremor has spotted